Hormone replacement therapy (HRT) supply issues

- The Department of Health and Social Care (DHSC) are aware of the ongoing manufacturing issues that have affected the supply of some hormone replacement therapy (HRT) products throughout 2019.
- Please see Table 1, which provides the latest update on the availability of all HRT products marketed in the UK and the known resupply date for products that's are currently experiencing supply issues.
- This table also provides an update of all HRT preparations that remain available. Clinicians may be required to switch patients to alternative HRT products that contain the same active ingredients for a temporary period.
- Prescribing information regarding HRT equivalence to support local decision making is available
 through various sources such as the British National Formulary, Summary of Product
 Characteristics (SPC), The Monthly Index of Medical Specialities (MIMS), and other sources
 including local Medicines Information Centres.
- Clinicians are advised to work closely with community pharmacies to understand local availability of HRT products and use the table below to help make decision about appropriative HRT products for patients who are affected by the supply issues.
- DHSC will continue to provide updates on HRT availability in the monthly supply report, which is uploaded to the Specialist Pharmacist Services website. All registered user can access this update via this following link: https://www.sps.nhs.uk/articles/department-of-health-and-pharmaceutical-market-strategy-group-pmsg-supply-updates/
- Please share this information with relevant networks locally including GP practices and community pharmacies.

Table 1. HRT Availability

| | | Oestrogen Only | | | | |
|-----------------------|------------------------|-------------------|----------|------------------------------------------------|------------------------------------------------------------------------------------------|--|
| Ingredient (s) | Manufacturer | Brand | Strength | Current Availability | Anticipated resupply | |
| | | Oral preparations | | | date | |
| Estradiol hemihydrate | Mylan | Elleste Solo* | 1mg | In stock | Continued availability to be confirmed. Please see below the | |
| | | | 2mg | In stock | table for more information on the Elleste range * | |
| | Mylan | Zumenon* | 1mg | OOS | Mid-September 2019 | |
| | | | 2mg | OOS | End of August 2019 | |
| Estradiol valerate | Bayer | Progynova | 1mg | In stock | | |
| Estradioi valerate | | | 2mg | In stock | | |
| Estradiol | Resource Medical UK | Bedol | 2mg | Long term OOS | | |
| | Transdermal patches | | | | | |
| Estradiol | Janssen-Cilag E | Evorel ** | 25 mcg | In stock until mid to end of February 2020 | Mid 2020 please see below the table for more information on the Evorel range**. | |
| | | | 50mcg | In stock until end of October 2019 | | |
| | | | 75mcg | In stock until beginning of October 2019 | | |

| | | | 100mcg | In stock until beginning of October 2019 | | |
|-----------------------|------------------------|------------------------------------------|--------------------|------------------------------------------------|------------------------|--|
| | | Estradot | 25 mcg | In stock | | |
| | | | 37.5mcg | In stock | | |
| | Novartis | | 50mcg | In stock | | |
| | | | 75mcg | In stock | | |
| | | | 100mcg | In stock | | |
| | Merus Labs/Norgine | Estraderm | 25 mcg | In stock | | |
| | | | 50mcg | In stock | | |
| | | | 75mcg | In stock | | |
| Estradiol hemihydrate | | | 100mcg | In stock | | |
| | | | 50mcg | In stock | | |
| | Theramex | FemSeven | 75mcg | In stock | | |
| | | Mono | 100mcg | In stock | | |
| | | Progynova | 50mcg | In stock | | |
| | Bayer | TS | 100mcg | In stock | | |
| | | Elleste Solo | 40mcg | In stock | Continued availability | |
| | Mylan | MX * | 80mcg | In stock | to be confirmed | |
| | | 1417 | 300mcg | In stock | to be committed | |
| Conjugated costrogen | Pfizer | Premarin | | | | |
| Conjugated oestrogen | Pilzer | | 625mcg | In stock | | |
| | T : 1/T | | 1.25mcg | In stock | | |
| | Besins | ransdermai geis/ I | creams/other deliv | ery systems) T | <u> </u> | |
| Estradiol | Healthcare (UK) Ltd | Oestrogel | 0.06% | In stock | | |
| | Orion | Sandrena | 0.5mg | In stock | | |
| | | | 1mg | In stock | | |
| Estradiol hemihydrate | Pfizer | Estring vaginal delivery system | 7.5mcg/ 24hours | In stock | | |
| | Novo Nordisk | Vagifem vaginal tablets | 10mcg | In stock | | |
| estriol | Flynn Pharma | Blissel | 50mcg/g | In stock | | |
| | Marlborough Pharma | Estriol cream (generic) | 0.01% | In stock | | |
| | Aspen | Ovestin cream | 1mg | In stock | | |
| Progestogen only | | | | | | |
| Medroxyprogesterone | Resource Medical UK | Climanor | 5mg | long term OOS | | |
| Levonorgestrel | Bayer | Mirena Intrauterine device | 20mcg/24hrs | In stock | | |
| Progesterone | Besins | Utrogestan | 100mg | In stock | | |
| | Healthcare (UK) Ltd | Utrogestan | 200mg | In stock | | |

| Combined HRTs (Progestogen and oestrogen) | | | | | | |
|----------------------------------------------------------------------------------------|-----------------------------|------------------------|-------------------------------|------------------------------------------|----------------------------------------|--|
| | Continuous combined therapy | | | | | |
| | | Oral p | reparations | | | |
| Estradiol hemihydrate / norethisterone acetate | Mylan | Elleste Duet Conti* | 2mg / 1mg | In stock at wholesalers | Continued availability to be confirmed | |
| | Novo Nordisk | Kliofem | 2mg/ 1mg | In stock | | |
| | | Kliovance | 1mg/ 500mcg | In stock | | |
| Estradiol hemihydrate / | Mylan | Femoston | 500mcg/ 2.5mg | In stock | | |
| dydrogesterone | | Conti | 1mg/5mg | In stock | | |
| Estradiol | Orion | Indivina | 1mg /2.5mg | In stock | | |
| valerate/medroxyprogeste | | | 2mg/5mg | OOS | End of August 2019. | |
| rone | | | 1mg/5mg | In stock | | |
| low dose conjugated oestrogen/medroxyproges terone | Pfizer | Premique | 300mcg/1.5mg | In stock | | |
| | | Transd | ermal patch | | | |
| Estradiol hemihydrate/ norethisterone acetate | Janssen-Cilag | Evorel Conti ** | 3.2mg/11.2mg | In stock - mid to end of October 2019 | Mid 2020 See below ** | |
| Estradiol hemihydrate/ levonorgestrel | Theramex | FemSeven C onti | 1.5mg/ 0.525mg | Long term OOS | Q2 2020 | |
| | | Sequential c | ombined therap | у | | |
| | | Oral p | reparations | • | | |
| Estradiol [X,X] / norethisterone acetate | Resource Medical UK | Clinorette | [2mg, 2mg]/ 1mg | Long term OOS | | |
| Estradiol/norgestrel | | Cyclo- progynova | 2mg/500mcg | Long term OOS | | |
| Estradiol hemihydrate / | Mylan | Elleste Duet | 1mg/ 1mg | In stock | Continued availability | |
| norethisterone acetate | | * | 2mg/ 1mg | In stock | to be confirmed | |
| Estradiol hemihydrate/ | | | Femoston | 1mg/ 10mg | limited stock | |
| dydrogesterone | | | 2mg/10mg | In stock | | |
| Estradiol hemihydrate / norethisterone acetate | | Novofem | 1mg/ 1mg | In stock | | |
| Estradiol valerate/ medroxyprogesterone acetate | Novo Nordisk | Tridestra | 2mg/20mg | In stock | | |
| Estradiol hemihydrate [X,X,X]/ norethisterone acetate | Orion | Trisequens | [2mg, 2mg, 1mg]/ 1mg | In stock | | |
| Transdermal patch | | | | | | |
| a) Estradiol hemihydrate and b) estradiol hemihydrate/ norethisterone acetate | Janssen-Cilag | Evorel Sequi** | a)3.2mg b) 3.2 mg /11.2 mg | In stock until mid- September 2019 | Mid 2020 See below ** | |
| a) 1.5mg of estradiol hemihydrate b) Estradiol hemihydrate /levonorgestrel | Theramex | FemSeven S equi | a) 1.5mg b) 1.5mg /1.5mg | Long term OOS | Q2 2020 | |
| Gonadomimetic (s) | | | | | | |
| Tibolone 2.5mg | Advanz Pharma | Livial tablets | Tibolone 2.5mg | In stock | | |

| Selective oestrogen receptor modulator | | | | | | |
|----------------------------------------|----------|---------|--------------|----------|--|--|
| Ospemifene 60mg tablets | Shionogi | Senshio | Ospemifene | In stock | | |
| | | tablets | 60mg tablets | | | |
| Tissue-selective oestrogen complex | | | | | | |
| | | | conjugated | | | |
| Conjugated oestrogen | | | oestrogen | | | |
| 300mcg/ bazedoxifene | Pfizer | Duavive | 300mcg/ | In stock | | |
| 20mg | | | bazedoxifene | | | |
| | | | 20mg | | | |

*Elleste HRT Range:

- Mylan have recently advised that supplies of all the Elleste Range (Elleste Duet Conti, Elleste
 Duet 2mg tablets, Elleste solo 1mg and 2mg tablets, Elleste Duet 1mg and 2mg and Elleste
 MX 40 and 80micrograms patches) have been replenished and are now available.
- However, Mylan have advised they are still experiencing on going manufacturing problems, therefore, currently they do not have visibility on future supplies.
- DHSC are working with Mylan and awaiting further information to understand the long-term implications of this.

**Evorel HRT transdermal patch range:

- Janssen-Cilag, the manufacturer of the Evorel HRT transdermal patch range (Evorel; Evorel Conti; Evorel Sequi) have notified the DHSC that due to manufacturing constrictions, the whole range will be out of stock from October 2019 for most presentations and others are expected to last until early 2020. Current forecasted stock out dates for specific Evorel products are listed in Table 1.
- Currently, Janssen-Cilag are unable to give an exact resupply date beyond mid-2020.
- UK Medicine Information have published guidance to advise on suitable alternatives. This
 provides a range of alternative options and highlights the need for prescribers to seek
 specialist advice for more complex patients and consider prioritising the use of transdermal
 HRT therapy for women at increased risk of venous
 thrombosis https://www.sps.nhs.uk/articles/shortage-of-evorel-hormone-replacement-therapy-hrt-patch-range/